[Show abstract][Hide abstract] ABSTRACT: Schnitzler syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain, and lymphadenopathy. Our objectives are to systematically review disease characteristics of Schnitzler syndrome and collect follow-up information to gain insight into treatment efficacy and long-term prognosis.
PubMed and MEDLINE databases (1966-2006) were searched, using the key words "Schnitzler syndrome," and the combination of "urticaria" with "monoclonal gammopathy," "immunoglobulin M (IgM)," or "paraproteinemia," as well as secondary references. Data on a total of 94 patients who met the criteria for Schnitzler syndrome were reviewed. Questionnaires sent to all authors retrieved additional follow-up data on 43 patients, resulting in a mean follow-up of 9.5 years after onset of symptoms, and a follow-up of 20 years or more in 10 patients.
Symptoms, signs, and laboratory findings as found in the 94 patients are reviewed in detail. There have been promising developments in therapeutic options, especially antiinterleukin-1 treatment, which induced complete remission in all 8 patients treated so far. To date, no spontaneous complete remissions have been reported. Patients with Schnitzler syndrome showed no increased mortality during the present follow-up. However, they had a 10-year risk of 15% of developing a lymphoproliferative disorder, most notably Waldenström's macroglobulinemia. Three cases of type amyloid A (AA) amyloidosis associated with Schnitzler syndrome were reported.
Schnitzler syndrome is a disabling disorder which affects multiple systems and which can be considered as an autoinflammatory syndrome. There are new, effective treatment options, but close monitoring remains warranted because of the increased risk of lymphoproliferative disease.
Seminars in Arthritis and Rheumatism 01/2008; 37(3):137-48. DOI:10.1016/j.semarthrit.2007.04.001 · 3.93 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Le syndrome de Schnitzler associe une gammapathie monoclonale de type IgM avec urticaire, fièvre intermittente, syndrome inflammatoire, douleurs osseuses, arthralgies et parfois, des adénopathies et/ou une hépatosplénomégalie. Il est rare, puisque seul 80 cas environ ont été rapportés. Le pronostic est dominé par le risque de survenue d’une hémopathie maligne. L’efficacité spectaculaire des inhibiteurs de l’IL1 dans des observations récentes offre de nouvelles perspectives pour la compréhension de la physiopathologie.
Revue du Rhumatisme 05/2008; 75(5):388-391. DOI:10.1016/j.rhum.2007.07.015
[Show abstract][Hide abstract] ABSTRACT: Schnitzler syndrome is characterized by monoclonal IgM gammopathy, urticaria, recurrent fever, evidence of inflammation, bone pain, and arthralgia, occasionally in combination with lymphadenopathy and/or hepatosplenomegaly. Only about 80 cases have been reported to date. Development of a hematological malignancy is the main complication. Recent reports of remissions induced by IL-1 receptor antagonist therapy shed new light on the pathophysiology of the disease.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.